SNP markers for predicting clinical response to anticancer drugs and prognosis in patients with non-small cell lung cancer and uses thereof

摘要

The present invention relates to two SNP markers present in the 3'-UTR of the PD-L1 gene, and a method of providing information for predicting the response and prognosis of anticancer drugs in patients with non-small cell lung cancer. Since the specific genotype of the SNP markers of the present invention is significantly correlated with the response to the paclitaxel-cisplatin chemotherapeutic agent treatment and the survival prognosis of patients with non-small cell lung cancer, the present invention provides a simple and efficient method for determining the reactivity and survival period of non- . / RTI